Novocure Ltd
NASDAQ:NVCR
Net Margin
Novocure Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| JE |
|
Novocure Ltd
NASDAQ:NVCR
|
2.1B USD |
-26%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
231.7B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
198.2B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
155.1B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
146.2B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.4B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
52.4B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
49.7B USD |
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.9B USD |
75%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
41.5B USD |
23%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
273.9B CNY |
31%
|
Novocure Ltd
Glance View
Novocure Ltd. operates in the intriguing intersection of medical innovation and patient-centric care, focusing on harnessing electric fields to treat cancerous tumors, a modality known as Tumor Treating Fields (TTFields). Founded in 2000 and based in the Isle of Jersey, the company has pioneered an unconventional approach that challenges traditional cancer treatments like chemotherapy and radiation. By deploying low-intensity, alternating electric fields through adhesive patches on the patient's body, TTFields interfere with the division of cancer cells, inhibiting tumor growth without the typical debilitating side effects. Novocure’s proprietary technology offers a unique, non-invasive treatment option primarily targeting aggressive cancers, such as glioblastoma and non-small cell lung cancer, positioning it as a notable innovator in the oncology space. The company's business model thrives on a blend of therapy innovation and strategic partnerships. Novocure generates revenue through sales of its wearable medical device, which continually delivers TTFields therapy. These sales are supplemented by the securing of insurance reimbursements, which is crucial for patient access and company profitability. By conducting numerous clinical trials, Novocure not only aims to expand the applicability of TTFields to other forms of cancer but also reinforces its value proposition to the healthcare community. Strategic collaborations with researchers and leading cancer centers further enhance its market penetration. As the company continues to invest in research and expand its treatment portfolio, its commitment to transforming cancer therapy by offering a new dimension of hope remains at the forefront of its mission.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Novocure Ltd's most recent financial statements, the company has Net Margin of -26.4%.
You don't have any saved screeners yet